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Lidoftazine is a calcium channel blocking agent that is
effective and safe in the treatment of angina pectoris,
but has been reported to be associated with sudden death
when administered for the treatment of supraventricular
arrhythmias. Studies were performed in dogs to deter-
mine if lidoflazine caused a rise in serum digoxin con-
centration that could cause arrhythmias or if it was di-
rectly arrhythmogenic. Dogsreceived chronic injections
of digoxin and then digoxin in combination with lido-
ftazine. No increase in digoxin concentration was found.
Several clinical studies (1-3) have shown the effectiveness
and safety of lidoflazine in the control of angina pectoris.
However, in patients with atrial fibril1ation receiving digi-
talis therapy and being treated with Iidoflazine to convert
the supraventricular arrhythmia. an increased frequency of
ventricular premature complexes and an enhanced propens-
ity for the development of serious ventricular arrhythmias
have been reported (4,5). Also , other investigators (6) have
reported an antiarrhythmic action of lidoflazine. Lidoflazine
has been shown to have an action similar to that of quinidine
in the treatment of supraventricular arrhythmias and is also
known to possess some of the calcium entry blocking effects
on supraventricular arrhythmias (7.8) . In view of recent
studies demonstrating a digoxin-quinidine interaction (9-10
and a digoxin-verapamil interaction (12-14) , it is reasonable
to postulate that lidoflazine may cause a rise in serum di-
goxin levels. These considerations suggest that concomitant
administration of lidoflazine and digitalis may be the cause
of the enhanced arrhythmogenicity . However . lidoflazine
itself may have arrhythmogenic activity and be the actual
cause of the enhanced myocardial vulnerability.
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Dogsalso underwent programmed electrical stimulation
while not receiving medications and then after incre-
mental doses of lidoftazine administered intravenously.
Lidoflazinedid not cause spontaneous ventricular tachy-
cardia and did not lower the threshold of ventricular
tachycardia induction. Combined administration of Ii-
doflazine and digoxin did not facilitate arrhythmia in-
duction. These studies do not support a digoxin-lido-
f1azine interaction or a direct arrhythmogenic action of
Iidoflazine.
Thus. we undertook studies in dogs to test if a digoxin-
lidoflazine interaction exists and causes a rise in serum di-
goxin levels . Another series of studies used programmed
electrical stimulation techniques to determine whether suc-
cessively greater doses of lidoflazine would lower the myo-
cardial threshold for the induction of ventricular tachy-
cardia . This was undertaken as a means of assessing the
proarrhythmic action of the drug.
Methods
Digoxin-Iidoflazine interaction. Eight mongrel dogs of
either sex, weighing between 25 and 35 kg, were housed
in the animal facilities for 7 days before drug administration.
All dogs were fed a standard diet. Dogs I to 5 (group I)
received digoxin , 0.02 mg/kg daily , for 9 days. On days 8
and 9, steady state digoxin levels were obtained. Concom-
itant adminstration of digoxin and lidoflazine was started
thereafter. Lidoflazine was injected for 14 days at 0.5 mgJkg
daily. Serum digoxin levels were obtained in these dogs
throughout the injection period of lidoflazine and digoxin
on days 6, 8, 10 and 13. Then Iidoflazine administration
was continued for an additional 6 days at double the dose
(1.0 rng/kg) , and serum digoxin level s were obtained on the
third day and last day of this injection period. Lidoflazine
was then injected at 2.0 rng/kg for 7 to 10 days, and digoxin
levels were monitored on days 4, 7 and 10. Dog 2 did not
survive the entire experiment and died because of pneu-
monia (determined at autopsy).
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DONS 6, 7 and 8 (group II) were given digoxin for 11
days hefore administration of lidoflazine. Digoxin levels
were monitored on days 9 and 11. After this determination,
lidoflazine was administered at 1.0 mg/kg for 6 days, and
digoxin levels were measured on days 3 and 6. Lidoflazine
was then injected at 2.0 mg/kg for 7 days, and digoxin
levels were monitored on days 4 and 7.
Lidoflazine and digoxin sample analysis. Samples of
blood obtained from the dogs receiving digoxin were ob-
tained. centrifuged and the serum analyzed in duplicate.
Standards consisting of serum from dogs not receiving drug,
to which was added a known concentration of lidoflazine,
demonstrated that levels of digoxin (0.09 ng/ml) were read-
ily and reliably detectable using a radioimmunoassay kit
(Travenol Labs) with radiolabeled (iodine-l 25) digoxin. The
assay was sensitive to 0.2 ng/ml digoxin. Control serum
samples in each dog did not reveal detectable amounts of
digoxin or other immunologically reacting substances. Li-
doflazine samples were determined by Janssen (Bersa. Bel-
gium I using high pressure liquid chromatographic analysis
sensitive to 25 ng/rnl.
Effectoflidoflazine on arrhythmogenicity. Nine dogs
of either sex, weighing 25 to 35 kg, were studied. The
animals were anesthetized with 10 mg/kg sodium pento-
barbital administered intravenously. Animals were intubated
with a cuffed endotracheal tube and ventilated with room
air. Body temperature was maintained at 37°C using radiant
heat A large bore catheter was inserted into the left femoral
artery to monitor systemic blood pressure using a Statham
P23Db transducer. Depth and rate of respiration were ad-
justed to maintain a partial pressure of oxygen (Po 2) greater
than 80 and pH between 7.35 and 7.45. A catheter was
placed in the left femoral vein for administration of addi-
tional fluid and medications. A 7 French hexapolar electrode
catheter was introduced through the right femoral vein into
the apex of the right ventricle.
Programmed stimulation protocol. The distal pair of
electrodes of the hexapolar catheter was used for right ven-
tricular stimulation and the middle or proximal pair for
intracardiac recording. All intracardiac electrograms were
filtered at 40 to 500 Hz and displayed on a multichannel
oscilloscope along with electrocardiographic leads I and
aVL; arterial blood pressure was recorded simultaneously.
Intracardiac electrical stimulation was performed utilizing
a Bloom stimulator generating square wave stimuli 2.0 ms
in duration with a stimulation intensity of 2.5 mAo Six beat
ventricular pacing (SIS,) with 8 second pauses between
trains was introduced at a basic cycle 20 to 30 ms shorter
than the dogs' own intrinsic cycle length. Premature ven-
tricular stimuli were delivered in late diastole after every
sixth pacing beat and moved progressively earlier until the
ventricular refractory period was reached. If one premature
ventricular stimulus (Sz) did not elicit ventricular tachy-
cardia, scanning with a second premature stimulus (S3) was
employed while placing Sz at 10 ms beyond the ventricular
refractory period. If S3 did not induce ventricular tachy-
cardia, then S4 and then S, were introduced sequentially.
All dogs underwent two control runs before administra-
tion of lidoflazine. Lidoflazine was then administered in
incremental doses of 0.5, 1, 2, 5 and 10 mg/kg at 30 minute
intervals. Programmed electrical stimulation was performed
30 minutes after administration of lidoflazine and before
administration of the next dose. Blood was withdrawn to
determine lidoflazine levels at each dose. If ventricular
tachycardia or ventricular fibrillation was induced, the ar-
rhythmia was terminated using burst pacing or defibrillation.
Electrolytes were monitored during the experiment and were
found to be within normal limits.
Lidoflazine anddigoxincombination. Additional elec-
trophysiologic studies were performed on six dogs that re-
ceived digoxin, 0.02 mg/kg intravenously, for 4 days. On
day 5, a digoxin serum sample was obtained and pro-
grammed electrical stimulation was performed as just de-
scribed. After initial programmed electrical stimulation
studies, lidoflazine was administered intravenously in in-
cremental doses of 2, 4 and 10 mg/kg, and programmed
electrical stimulation was repeated 30 minutes after each
dose.
Statistical analysis. The data obtained were analyzed
for the presence or absence of ventricular tachycardia and
to determine if these arrhythmias were abolished, reduced
or augmented by the drugs. Data are reported as mean values
± standard error of the mean. Differences between means
were determined using Students t test. A two-tailed test was
employed to determine the level of significance.
Results
Long-term administration of digoxin and then digoxin in
combination with lidoflazine was performed to determine if
lidoflazine caused a rise in serum digoxin concentration.
All dogs achieved a steady state digoxin level before li-
doflazine administration. The mean serum digoxin levels
were monitored on days 8 and 9. In Dogs 1 to 5, at the end
of 8 and 9 days of digoxin administration, mean serum
digoxin concentration was 2.2 ± 0.5 and 2.1 ± 0.5 ng/ml,
respectively. Fifteen days of lidoflazine injection (0.5 mg/kg)
did not produce a significant change in mean serum digoxin
level (1.6 ± 0.8 ng/ml). Additional injections of lidoflazine
(2.0 mg/kg) for the next 10 days caused no change in serum
digoxin concentration. The mean digoxin concentrations for
all dogs at the incremental doses of lidoflazine are reported
in Table 1. At the end of the injection period, electrocar-
diographic monitoring did not show any ventricular
arrhythmias.
Lidoflazine inducibility studies. Nine dogs underwent
sequential programmed electrical stimulation studies. Eight
of the nine dogs could not have ventricular tachycardia or
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Table 1. Effect of Lidoflazine on Serum Digoxin Concentration
Lidoflazine Duration of Drug Digoxin Serum
Dose Administration Concentration
Drug Injected (mg) (days) (ng/rnl)
Digoxin a 8 2.1 ± 0.6
a 9 2.0 ± 0.5
Digoxin and 0.5 7 2.4 ± 0.6
Iidoflazine 0.5 9 1.7 ± 0.2
0.5 12 2.0 ± 0.3
0.5 14 2.1 ± 0.6
1.0 3 1.7 ± 0.5
1.0 5 1.7 ± 0.8
2.0 3 1.0 ± 0.1
2.0 6 1.6 ± 0.6
2.0 9 1.8 ± 0.5
ventricular fibrillation induced in the initial control period
(Table 2). Incremental doses of lidoflazine caused succes-
sive increases in blood lidoflazine levels (Table 3). Dog 8,
in which ventricular tachycardia was initially inducible by
three extrastimuli, was later found to have a significant
pericardial effusion and signs of myocarditis. Of the eight
dogs in which ventricular arrhythmias were not inducible,
successive doses of lidoflazine of 0.5, 1,2,5 and 10 mg/kg
did not change the pattern of inducibility. In Dog 9, ven-
tricular arrhythmia became inducible at a lidoflazine dose
of 1 mg/kg. However, this could not be repeated after mul-
tiple attempts and with additional doses of lidoflazine, ven-
tricular tachycardia was not inducible.
In Dog 8, ventricular arrhythmia that was initially in-
ducible during the control study remained inducible after
successive doses of lidoflazine. No change was noted in the
number of extrastimuli needed to induce ventricular tachy-
cardia. Right ventricular effective refractory period was de-
termined using the extrastimulus technique (Table 3). The
high doses of lidoflazine studied caused an increase in the
effective refractory period of the right ventricle. When the
dog was receiving no medications, the effective refractory
period for the first extrastimulus was 130 ± 13 ms: at 10
mg/kg, this increased to 163 ± 20 ms. The differences for
the second, third and fourth extrastimuli were less.
Mean heart rate was observed to decrease with incre-
mental doses of lidoflazine, from 190 ± IS beats/min ini-
tially to 168 ± 20 beats/min at 2 mg/kg and to 131 ± 30
at 10 mg/kg (Table 4). No significant effect on either PR
or QRS duration was noted. The QT interval increased from
181 ± 19 ms initially to 223 ± 34 ms at 10 mg/kg. Both
systolic and diastolic blood pressures decreased with incre-
mental doses of lidoflazine.
Lidoftazine and digoxin inducibility studies. Six dogs
received digoxin, 0.02 mg/kg intravenously. for 4 days. On
day 5, the serum digoxin concentration was 1.8 ± 0.3
ng/ml. Programmed electrical stimulation was performed
and all dogs had ventricular tachycardia induced that de-
generated into ventricular fibrillation requiring defibrillation
to terminate the arrhythmia. After the initial induction, 2
mg/kg of lidoflazine was administered intravenously, and
after 30 minutes, programmed electrical stimulation re-
peated. Ventricular arrhythmia was still inducible in six
dogs, and no change was noted in the number of stimuli
needed to provoke the arrhythmia. This pattern was also
noted after 4 and 10 mg/kg of lidoflazine was administered.
Despite a 27% increase in the QT interval and a 16% in-
crease in ventricular refractoriness, lidoflazine did not pre-
vent or facilitate arrhythmia induction. During the entire
experiment, continuous electrocardiographic monitoring was
performed and no spontaneous ventricular ectopic activity
was noted.
Discussion
Lidoflazine, an orally effective antianginal agent with
long-acting coronary vasodilator effects, has been demon-
strated to be highly effective in the treatment of angina
pectoris (1-3). A series of studies (5.6) over the last decade
reported that lidoftazine may also possess some antiar-
Table 2. Inducibility of Ventricular Arrhythmia With Incremental Doses of Lidoflazine
Lidoflazine Dose
Dog Control I Control 2 0.5 mg/kg I rng/kg 2 mg/kg 5 mg/kg 10 mg/kg
I No No No No No No No
2 No No No No No No No
3 No No No No No No No
4 No No No No No No No
5 No No No No No No No
6 No No No No No No No
7 No No No No No No No
8* Yes Yes Yes Yes Yes No Yes
9 No No No No No No No
*Pericardial effusion and myocarditis. No and yes indicate, respectively, that ventricular tachycardia or
fibrillation was not or was provoked.
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Table 3. Right Ventricular Effective Refractory Period (rns) at Increasing Lidoflazine Doses in
Nine Dogs
Lidoflazine Lidoflazine
Dose Concentranon
(rng/kg) s, S3 S4 s, (ng/ml)
Baseline 130 ± 13 116 ± 25 118 ± 34 120 ± 34
0.5 136 ± 12 128 ± 29 134 ± 40 130 ± 21 149 ± 58
I 151 ± 17* 130 ± 32 140 ± 47 133 ± 30 181 ± 46
2 151 ± 18* 132 ± 31 135 ± 28 126 ± 19 247 ± 108
5 155 ± 14t 142 ± 28 135 ± 22 136 ± 37 698 ± 330
10 163 ± 20t 135 ± 19 120 ± 20 143 ± 42 1,539 ± 601
*p<0.05 and tp<O.OI versus baseline values. Sz duration (ms) from end ofpacmg train tofirst extrastimlus;
S3 duration from first to second extrasumulus; S4 duration from second to third extrastimulus; S,duration from
third to fourth extrastimulus
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rhythmic properties, specifically against atrial arrhythmias,
and may cause pharmacologic cardioversion of atrial fi-
brillation, However, the drug was allegedly associatedwith
the productionof ventricularectopic activity. includingven-
tricular fibrillation leading to syncope and death. The pa-
tients showing this possible enhanced susceptibility to li-
doftazine-induced arrhythmias seemed to be in significantly
worse condition than other patients. They manifested
congestive heart failure, were receiving digitalis therapy
(4.5) and were elderly and in many instances debilitated.
Interaction between calcium channel blocking agents
and digoxin. Our study tested the hypothesis that either
lidoftazine itself produces enhanced myocardial vulnerabil-
ity or there is an interaction between lidoftazine and digoxin
after concomitant drug administration, similar to the inter-
action observed between digitalis and quinidine (9-11) and
digitalis and verapamil (12,13). Belz et al. (15) reported
that in addition to quinidine. other antiarrhythmic drugs and
various calcium antagonists interact with digoxin and cause
a rise in serum digoxin concentration in human subjects.
Verapamil caused a 70% rise in digoxin concentration; ni-
fedipine and gallopamil resulted in a 45 and 16% increase,
respectively. Propafenone and quinidine, both type 1drugs
with known proarrhythmic effects. caused a 37 and 118%
increase, respectively, in digoxin levels. Klein et a1. (13)
noted that the increase in digoxin concentration caused by
verapamil is dose-dependent and gradual over a period of
weeks. Pedersen et a1. (16) suggested that a decrease in
renal tubular secretion of digoxin may be responsible for
increased digoxin levels after verapamil treatment. Nife-
dipine was found by Belz et a1. (17) to increase digoxin
serum concentrations by 45%, Moysey et a1. (18) observed
a 69% increase in digoxin concentration by administration
of amiodarone. Both amiodarone and digoxin are avidly
tissue-bound, and it is possible that amiodarone displaces
tissue-bound digoxin or interferes with digoxin excretion.
Klein et a1. (13) observed signs of digoxin intoxication
in 7 of 49 patients receiving combined digoxin-verapamil
therapy. However, serious arrhythmias seem to occur less
frequently with this combination than with digoxin-quini-
dine administration (13,14,19-21). Verapamil has beenshown
to depress digoxin-induced rhythmdisturbances (22), whereas
quinidine tends to provokearrhythmiaswhen combinedwith
digoxin, Thus, the risk of digoxin toxicity during verapamil
therapy may be less than that during quinidine therapy.
Because lidoflazine has calcium antagonist properties, it
might cause an increase in serum digoxin concentration,
However, our results in dogs show that serum digoxin con-
centration did not change after lidoftazine administration
over a wide dosage range and prolonged administration (4
weeks), Similar studies with quinidine showed a doubling
of serum digoxin concentration within 72 hours. Further-
Table 4. Effect of Incremental Doses of Lidoflazine on Blood Pressure and Electrocardiographic Variables in Nine Dogs
Lidoflazine
Dose HR PR QRS QT Systolic BP Diastolic BP
(mg/kg) (beats/min) (ms) (rns) (ms) (mmHg) (mm Hg)
Baseline 190 ± 15 100 ± 10 42 ± 6 181 ± 19 127 ± 22 84 ± 13
05 176 ± 19 99 ± 5 43 ± 6 198 ± 15 122 ± 25 79 ± 14
I 168 ± 19 100 ± 9 44 ± 5 202 ± 20* 117 ± 19 78 ± 17
2 168 ± 20 97 ± 7 44 ± 5 204 ± 26 121 ± 23 76 ± 16
5 152 ± 22 97 ± 4 44 ± 6 211 ± 22 110 ± 20 63 ± 12t
10 131 ± 30t 99 ± 9 45 ± 5 233 ± 34t 100 ± 27 56 ± 18t
'p<O.05 and tp<O.OI versus baseline value, BP = blood pressure; HR = heart rate.
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more, verapamil administered over a period of 15 days
provided a 75% increase in serum digoxin concentration
(12). Similar results have been found in patients (13). The
period of our study (3 to 4 weeks) is the time frame in which
patients receiving lidoflazine and digoxin were reported to
have enhanced ventricular arrhythmias. Thus, a lidoflazine-
digoxin interaction does not explain the reported arrhyth-
mogenicity of lidoflazine in patients receiving both digoxin
and lidoflazine.
Arrhythmogenicity of Iidoflazine. The hypothesis that
lidoflazine may possess proarrhythmic activity was not sup-
ported by the results of our canine electrophysiology studies
introducing successively greater doses of lidoflazine. With
incremental doses of lidoflazine, we observed an increase
of lidoflazine serum concentration. However, incremental
doses of lidoflazine did not change the inducibility pattern
of ventricular arrhythmia in normal dogs. Furthermore, in
the one dog in which ventricular arrhythmia was inducible,
successive incremental doses of lidoflazine did not alter the
number of extrastimuli needed to provoke ventricular tachy-
cardia. Using compounds that are arrhythmogenic, such as
digoxin, successive incremental doses make the dog more
vulnerable to induction of ventricular tachycardia and ven-
tricular fibrillation and reduce the number of extrastimuli
needed to provoke ventricular tachycardia.
The assessment of arrhythmogenicity is determined using
the technique of programmed electrical stimulation, which
has been shown effective in predicting those patients at risk
for sudden death (23) and in helping to select long-term
antiarrhythmic therapy (24,25). Other investigators have
also used programmed electrical stimulation techniques to
identify potentially arrhythmogenic situations such as those
induced by alcohol (26), cateeholamines (27), cigarette smoke
(28), caffeine (29) and antiarrhythmic agents (30). In fact,
using invasive electrophysiologic techniques, Velebit et al.
(31) found an appreciable incidence of arrhythmogenicity
for most conventional and experimental antiarrhythmic drugs.
Because most of the patients with the possible proar-
rhythmic action of lidoflazine were also receiving digoxin,
the two drugs in combination may be proarrhythmic. How-
ever, incremental doses of lidoflazine did not change the
inducibility pattern and did not cause ventricular premature
complexes in dogs that received digitalis. Thus, neither
lidoflazine alone nor lidoflazine in combination with digoxin
showed an arrhythmogenic action.
Effectonsinoatrialandatrioventricularnodal function.
Progressively greater doses of lidoflazine caused a dose-
dependent slowing in heart rate with no effect on PR in-
terval. This suggests a greater effect of lidoflazine on si-
noatrial node automaticity as contrasted to atrioventricular
(AV) node conduction. Interestingly, these properties are
also shared by another calcium channel blocking agent,
bepridil, an agent that also prolongs the QT interval. Re-
polarization changes and an exclusive or greater effect on
sinoatrial node automaticity as compared with AV node
conduction clearly differentiate these drugs from other cal-
cium channel blocking agents. Hypocalcemia may homo-
geneously lengthen the QTc interval, and arrhythmogenicity
in hypocalcemic syndromes is rare unless complicated by
hypokalemia. Although calcium channel blockade could cause
a prolongation in the time course of repolarization, the marked
effect of lidoflazine and bepridil and the lack of clinical
effect on repolarization of verapamil, diltiazem and nife-
dipine, suggest another mechanism besides the action on
calcium movement. The differential effects on heart rate
and PR interval may result from different subtypes of cal-
cium channels at the sinoatrial and AV nodes.
Clinical implications. Since lidoflazine failed to effect
myocardial vulnerability, the drug does not seem to have a
measurable arrhythmogenic potential. How can we then ex-
plain the high mortality rates in some studies of lidoflazine
and patients with atrial fibrillation? Certainly, the patients
in the lidoflazine-treated group were sicker, a factor that
may be contributory. Furthermore, a higher incidence of
sudden death is noted in patients with atrial fibrillation (32).
It is possible that atrial fibrillation lowers myocardial thresh-
old and this lowered threshold in combination with extensive
myocardial disease and further prolongation of repolariza-
tion by lidoflazine is proarrhythmic. In the present study,
high doses of lidoflazine failed to alter myocardial threshold
to ventricular arrhythmia, casting doubt on the suggestion
that lidoflazine facilitates or initiates cardiac arrhythmias.
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